This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.80% per year. These returns cover a period from January 1, 1988 through August 3, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
cancer: Archive
Oncology Stocks to Add to Your Portfolio as Cancer Care Evolves
by Kinjel Shah
Oncology innovation is driving new treatment options, with Iovance, Merit Medical and Kura advancing cancer-focused therapies and technologies.
MMSIPositive Net Change KURANegative Net Change IOVANegative Net Change AZNNegative Net Change NVSNegative Net Change JNJPositive Net Change PFENegative Net Change
cancer pharmaceuticals
5 Biotech Stocks Worth Adding to Your Portfolio Now
by Ekta Bagri
New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position HALO, RGEN, IOVA, ARQT and PGEN in this volatile sector.
HALONegative Net Change RGENNegative Net Change IOVANegative Net Change PGENNegative Net Change ARQTNegative Net Change
biotechnology biotechs cancer medical pharmaceuticals
PRPO vs. BDSX: Which Cancer Diagnostics Stock Is the Better Buy Now?
by Debanjana Dey
Precipio and Biodesix take different approaches to cancer diagnostics, but which stock looks more compelling now? Let's dive in.
PRPONegative Net Change BDSXNegative Net Change
cancer medical oncology-screening
Moderna or Merck: Which Soaring Cancer Vaccine Stock Is the Better Buy?
by Shaun Pruitt
Shares of Moderna (MRNA) and Merck (MRK) are soaring Wednesday after the companies reported a potentially historic breakthrough for their personalized mRNA cancer vaccine.
MRKNegative Net Change MRNANegative Net Change
biotechnology cancer cell-therapy dividends genetics hospitals immuno-therapy investing large-cap medical pharmaceuticals
Earnings, Cancer Vaccine, Long-Term Liquidity: A Busy Pre-Market
by Mark Vickery
Q2 retail earnings continue, Moderna sees positive Phase 3 results, and the Treasury lowers the longer-term bond rate.
MRKNegative Net Change TGTNegative Net Change TJXPositive Net Change LOWPositive Net Change ELNegative Net Change MRNANegative Net Change
biotechnology biotechs cancer earnings finance
BMY Rallies 16.2% in Three Months: Buy, Sell or Hold the Stock?
by Ekta Bagri
Bristol Myers Squibb's Growth Portfolio and pipeline support momentum, but generic headwinds and recent gains call for a cautious stance.
BMYNegative Net Change PFENegative Net Change MRKNegative Net Change
biotechnology biotechs cancer medical pharmaceuticals
UnitedHealth vs. Centene: Which Managed Care Stock Is the Better Buy?
by Rajshree Sipani
UNH's diversified platform, AI expansion and Optum momentum strengthen its long-term outlook, making it the stronger managed care pick over CNC.
UNHNegative Net Change CNCNegative Net Change
artificial-intelligence automation cancer healthcare hmo hospitals insurance insurance-premium medical pharmaceuticals smart-health staffing
BIAF vs. BDSX: Which Cancer Diagnostics Stock Is the Better Buy Now?
by Debanjana Dey
bioAffinity and Biodesix pursue different cancer diagnostics strategies, but which oncology stock offers better long-term upside? Let's dive in.
BDSXNegative Net Change BIAFNegative Net Change
biotechnology biotechs cancer medical oncology-screening
CSBR vs. CTKB: Which Life Sciences Stock Has Better Long-Term Upside?
by Debanjana Dey
Champions Oncology and Cytek Biosciences have different growth drivers and valuations, but which life sciences stock offers better long-term upside? Let's dive in.
CSBRNegative Net Change CTKBPositive Net Change
biotechnology biotechs cancer medical oncology-screening
2 Microcaps With Gross Margin Catalysts
by Mark Zinski
CSBR and CEPL have levers in place for Gross Margin improvement.
CSBRNegative Net Change CEPLNegative Net Change
cancer energy healthcare utilities